Starting with the world’s best science,
we build world-changing businesses.

Since 2015, we have worked with over 200 of Oxford’s leading academics to build a portfolio of more than 100 companies, worth over $2 billion, all based on Oxford science.

From the Oxford-vaccine to breakthroughs in quantum computing, nuclear fusion and advanced medical diagnostics, our companies all have the potential to positively impact lives on a global scale.

Scientific breakthroughs can solve the world’s toughest problems, from infectious diseases to natural resource shortages and rapid climate change, but only when they make it out of the lab.

We build world-changing businesses, bringing Oxford science to the world faster.


YASA has been acquired by Mercedes-Benz AG – the acquisition will accelerate the impact of YASA’s world-leading technology, supporting adoption of electric vehicles on a global scale

Read more

Orbit Discovery Announces $7.6 Million funding to accelerate growth in peptide discovery business

Read more

Perspectum Launches New Clinical Study to Investigate Integrated Diagnostics to Enable Precision Medicine for Liver Cancer Patients

Read more

Vaccitech have entered into a Phase 2a clinical trial collaboration agreement with Arbutus Biopharma Corporation to evaluate an innovative combination of their therapeutic technologies for the treatment of patients with chronic HBV infection

Read more

OQC delivers the UK’s first Quantum Computing as-a-Service

Read more

Introducing our newest Scientist in Residence: Sarah Leonard

Read more

Ultromic’s EchoGo Predicts Cardiac-Related COVID-19 Mortality Revealed in WASE Study

Read more

UK Science Minister Amanda Solloway MP launches First Light Fusion’s maiden ‘Big Gun’ fusion campaign

Read more

Caristo Diagnostics, Navenio and Perspectum are three of the 38 winners of the NHSX AI Lab’s second wave of AI in Health and Care Awards

Read more

DNV verifies Brill Power’s new battery management system technology

Read more

Oxford University academics recognised in Queen’s Birthday Honours – including Vaccitech co-founders

Read more

Nucleome Therapeutics has published its novel 3D genome analysis method, a significant advancement in the field, in the journal Nature

Read more
More News


VR-empowered #mentalhealth company @Rey have raised $10 million in new investment, $26 million in total - since launching in April 👏

Rey’s parent company, @Oxford_VR_Ltd, was spun out of @UniofOxford's Psychiatry department

Read more in @Forbes ⬇️

From Ops to Finance, from Hardware to Software, we're currently hiring in all departments. You don't (always) need #quantum experience and we offer great benefits + a fab team. Join us!


We're excited to share the news that @YASAMotors has been acquired by @MercedesBenzUK.

This acquisition will further accelerate the positive impact of YASA's world-leading technology - supporting the adoption of electric vehicles globally.

#electricvehicles #oxford #automotive

Financial Times@FT

Mercedes buys UK start-up Yasa as it steps up electric transition

Stay up to date

Get the latest on cutting-edge developments in our portfolio, straight to your inbox.